Cas No.: | 474645-27-7 |
名称: | (S)-N-((3R,4S,5S)-1-((S)-2-((1R,2R)-3-(((1R,2R)-1-Hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-3-methoxy-5-methyl-1-oxohe;[3H]-Vedotin;MMAE;MMAE(Monomethyl Auristain E);MONOMETHYL AURISTATIN E;Vedotin;N-Methyl-L-valyl |
别名: | MMAE, SGD-1010 |
SMILES: | CN[C@H](C(N[C@H](C(N(C([C@@H](CC(N1CCC[C@H]1[C@@H]([C@H](C(N[C@@H]([C@H](C1C=CC=CC=1)O)C)=O)C)OC)=O)OC)[C@H](CC)C)C)=O)C(C)C)=O)C(C)C |
分子式: | C39H67N5O7 |
分子量: | 717.97859120369 |
纯度: | >99% |
保存条件: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | Monomethyl auristatin E (MMAE, vedotin) is a very potent anti-mitotic agent that inhibits cell division by blocking the polymerisation of tubulin. Because of its super toxicity, it cannot be used as a drug itself. In recent cancer therapy developments, it is linked to a monoclonal antibody (mAb) that recognizes a specific marker expression in cancer cells and directs MMAE to the cancer cells. The linker linking MMAE to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the antibody-drug-conjugate/ADC has bound to the specific cancer cell antigen and entered the cancer cell, thus releasing the toxic MMAE and activating the potent anti-mitotic mechanism.For the detailed information of Monomethyl auristatin E (MMAE, vedotin), the solubility of Monomethyl auristatin E (MMAE, vedotin) in water, the solubility of Monomethyl auristatin E (MMAE, vedotin) in DMSO, the solubility of Monomethyl auristatin E (MMAE, vedotin) in PBS buffer, the animal experiment (test) of Monomethyl auristatin E (MMAE, vedotin), the cell expriment (test) of Monomethyl auristatin E (MMAE, vedotin), the in vivo, in vitro and clinical trial test of Monomethyl auristatin E (MMAE, vedotin), the EC50, IC50,and Affinity of Monomethyl auristatin E (MMAE, vedotin), Please contact DC Chemicals. |
In Vivo: | |
In Vitro: | |
References: |
Kinase Assay: | |
Cell Assay: | |
Animal Administration: | |
References: |